Merus (MRUS): FDA Approval and Speculative Future in Cancer Therapy
We recently published a list of Jim Cramer’s Lightning Rounds: 12 Stocks Under the Spotlight. In this article, we are going ...
Promising Potential of Merus’s Petosemtamab in HNSCC: A Buy Recommendation
Bank of America Securities analyst Tazeen Ahmad maintained a Buy rating on Merus (MRUS – Research Report) yesterday and set a price target of ...
Merus Positioned for Growth Amid Promising Clinical Data and Resilience to Market Fluctuations
Leerink Partners analyst Andrew Berens has maintained their bullish stance on MRUS stock, giving a Buy rating yesterday.Pick the best stocks ...
Citigroup Issues Positive Forecast for Merus (NASDAQ:MRUS) Stock Price
Merus (NASDAQ:MRUS – Get Free Report) had its price target hoisted by research analysts at Citigroup from $89.00 to $97.00 in ...
Merus Scores Its First FDA Approval For Lung Cancer Drug
Bizengri (zenocutuzumab-zbco) as the first and only treatment indicated for adults with pancreatic adenocarcinoma or ...
FiercePharma7d
FDA signs off on Merus' first-in-class NRG1+ cancer drug Bizengri after brief delay
Merus’ week keeps getting better. Days after securing a long-awaited commercialization partner for its zenocutuzumab, the ...
US FDA approves Merus' therapy to treat lung, pancreatic cancers
The U.S. Food and Drug Administration has approved Merus NV's therapy that targets a particular gene, expanding treatment ...
Merus (NASDAQ:MRUS) Given “Buy” Rating at Needham & Company LLC
Needham & Company LLC reaffirmed their buy rating on shares of Merus (NASDAQ:MRUS – Free Report) in a report published on Monday,Benzinga reports. The firm currently has a $85.00 price target on the ...
FierceBiotech9d
Merus' head and neck cancer candidate bolsters 'best-in-disease' profile with new data drop: analyst
With new data on petosemtamab set to be presented at the European Society for Medical Oncology Asia Congress, Merus believes ...
Cramer's Lightning Round: Merus is ‘very speculative'
Mad Money” host Jim Cramer rings the lightning round bell, which means he’s giving his answers to callers’ stock questions at ...
Merus Licenses US Commercialization Rights For Cancer Potential Zenocutuzumab, Analyst Highlight Merus' Pipeline
Merus partners with Partner Therapeutics for U.S. rights to Zeno in NRG1+ cancer. Updated petosemtamab data emerge as a key ...
Yahoo Finance4d
Merus’ Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 07, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology ...